Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2006, p. 561-570, Vol. 44, No. 2
0095-1137/06/$08.00+0 doi:10.1128/JCM.44.2.561-570.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Departments of Urology,1 Medicine,2 Biomathematics,4 Human Genetics,5 Pathology and Laboratory Medicine,6 Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California 90095,7 GeneFluidics Inc., Monterey Park, California 91754,3 Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 900738
Received 28 July 2005/ Returned for modification 28 October 2005/ Accepted 13 November 2005
|
|
|---|
|
|
|---|
Recent engineering advances have enabled the development of electrochemical DNA biosensors with molecular diagnostic capabilities (2, 8, 18, 33, 47). Electrochemical DNA biosensors offer several advantages compared to alternative molecular detection approaches, including the ability to analyze complex body fluids, high sensitivity, compatibility with microfabrication technology, a low power requirement, and compact instrumentation compatible with portable devices (18, 48). Electrochemical DNA sensors consist of a recognition layer containing oligonucleotide probes and an electrochemical signal transducer. A well-established electrochemical DNA sensor strategy involves "sandwich" hybridization of target nucleic acids by capture and detector probes (5, 7, 46, 50). In this strategy, the target is anchored to the sensor surface by the capture probe and detected by hybridization with a detector probe linked to a reporter function. Detector probes coupled to oxidoreductase reporter enzymes allow amperometric detection of redox signals by the sensor electrodes (28, 34). When a fixed potential is applied between the working and reference electrodes, enzyme-catalyzed redox activity is detected as a measurable electrical current (11, 16, 27). The current amplitude is a direct reflection of the number of target-probe-reporter enzyme complexes anchored to the sensor surface. Because the initial step in the electrochemical detection strategy is nucleic acid hybridization rather than enzyme-based target amplification, electrochemical sensors are able to directly detect target nucleic acids in clinical specimens, an advantage over nucleic acid amplification techniques, such as PCR.
Ultrasensitive target detection by amperometric sensors requires electrodes with surface properties that provide an extremely high signal-to-noise ratio. Advances in microfabrication technology have allowed production of a novel electrochemical sensor array consisting of 16 sensors with optical-grade surface characteristics. The electrodes in each sensor are deposited onto a plastic support in the form of a 50-nM-thick gold film with a minimum of surface irregularities (17). The smoothness of the gold allows the sensor surface to be coated with a densely packed chemical self-assembled monolayer (SAM) that insulates the electrode from background noise (6). In this study, a panel of oligonucleotide capture and detector probe pairs was developed for the sensor array to function as a "UTI chip" for detection and identification of uropathogens. This culture-independent electrochemical sensor strategy is rapid, requiring approximately 45 min from sample acquisition to data readout, and does not require labeling or amplification of the 16S rRNA target. A blinded clinical study involving urine specimens from patients at risk of UTI demonstrated that the performance of the UTI chip was comparable to that of routine clinical microbiology studies. This report confirms the feasibility of direct detection and species-specific identification of bacterial pathogens in clinical specimens using an electrochemical DNA biosensor.
|
|
|---|
Probe design. Species- and group-specific capture and detector probe pairs were designed using a bioinformatics-based approach (M. A. Suchard, J. C. Liao, M. Mastali, M. M. Kelley, and D. A. Haake, unpublished data) that compared 16S rRNA gene sequences obtained from the NCBI database (Bethesda, MD) and from uropathogen isolates with the estimated hybridization accessibilities of 16S rRNA target sequences (14). In addition to species- and group-specific probe pairs, a universal probe pair was designed to hybridize with all bacterial 16S rRNA gene sequences. Both capture and detector probes were 27 to 35 bp in length, with their hybridization sites typically separated by a gap of 6 bp. Capture and detector probes were synthesized with 5' biotin and 5' fluorescein modifications, respectively (MWG, High Point, NC).
Electrochemical sensor array. Electrochemical sensor arrays were provided by GeneFluidics (Monterey Park, CA). As shown in Fig. 1A, each sensor in the 16-sensor array consisted of a central working electrode surrounded by a reference electrode and an auxiliary electrode. The single-layer electrode design populated with alkanethiolate SAM surface modifications was described previously (16), with modifications in the electrode configuration and fabrication process. Sensor arrays used in the current study were batch fabricated by deposition of a 50-nm gold layer onto a plastic substrate. Forty microliters of 0.1 mM K3Fe(CN)6 (potassium hexacyanoferrate; Sigma, St. Louis, MO) was applied to each sensor, and cyclic voltammetry (3) was performed using a chip mounter (Fig. 1B) and a 16-channel potentiostat (GeneFluidics) as a quality control measure to characterize the alkanethiolate SAM on the sensor surface. Sensors found to have peak cyclic voltammetry currents of >100 nA were rejected to avoid sensors with incomplete SAM insulation, which would result in excessive background noise during amperometric measurement. This and each of the subsequent steps was followed by washing with a stream of deionized H2O applied to the sensor surface for approximately 2 to 3 s and drying for 5 s under a stream of nitrogen. The carboxyl termini of the SAM alkanethiols were activated and functionalized as previously described (17). In brief, each working electrode was incubated with 2.5 µl of 100 mM N-hydroxysuccinimide-400 mM N-3-dimethylaminopropyl-N-ethylcarbodiimide for 10 min. The activated sensors were incubated in biotin (5 mg/ml in 50 mM sodium acetate; Pierce, Rockford, IL) for 10 min. The biotinylated sensors were incubated in 4 µl of 0.5 U/ml of streptavidin in RNase-free H2O (catalog no. 821739; MP Biomedicals, Aurora, OH) for 10 min. The streptavidin-coated sensors were incubated with biotinylated capture probes (4 µl; 1 µM in 1 M phosphate buffer, pH 7.4) for 30 min.
![]() View larger version (47K): [in a new window] |
FIG. 1. Components and performance of the electrochemical sensor. (A) The 16-sensor array (2.5 by 7.5 cm) was microfabricated with a thin, optical-grade layer of gold electrodes deposited on plastic. Each sensor in the array contained three electrodes: a central working electrode, a circumferential reference electrode, and a short auxiliary electrode. (B) The chip mounter with contact pins for simultaneous reading of the current output from each of the sensors in the array. (C) Detection strategy. (1) Bacterial lysis to release 16S rRNA target (black dashed line). (2) Hybridization of the target with the fluorescein (green circle)-labeled detector probe (blue line). (3) Hybridization of the target with the biotin (red circle)-labeled capture probe (orange line). (4) Binding of anti-fluorescein antibody conjugated with HRP to the target-probe sandwich. (5) Generation of current by transfer of electrons to the electron transfer mediator, TMB. (D) Current output in an experiment involving a clinical urine specimen containing K. pneumoniae showing signal stabilization from all 16 sensors in the array within 60 seconds. Probe results were obtained by averaging the log10 current outputs from duplicate sensor readings at 60 seconds.
|
Clinical-validity study design. Clinical urine specimens from routine urine cultures collected from inpatients and outpatients were received and submitted to the UCLA Clinical Microbiology Laboratory. Routine plating on trypticase soy agar with 5% sheep blood was performed on each specimen for phenotypic identification and colony counting, while an aliquot of each specimen was held at 4°C overnight. On the day after being plated, specimens were selected for inclusion in the study on the basis of a rapid indole test for the purpose of including uropathogens other than Escherichia coli in approximately one-half of the specimens. The other half of the specimens were divided between E. coli-containing specimens and specimens determined to have "no significant growth" or "no growth" (see definitions below). Because most UTIs involve a single uropathogen, specimens determined by the clinical microbiology laboratory to have more than one organism present were excluded. Blinded specimens selected for inclusion in the study were stripped of patient identifiers and any microbiological data before delivery to the research laboratory for testing with the electrochemical sensor array.
Experiments were performed on all specimens using the 16-sensor array "UTI chip," in which the UNI, EB, EC, PM, KE, PA, and EF capture probes (defined in Tables 1 and 2) were tested in duplicate. The two remaining sensors served as negative controls (including capture and detector probes without bacterial lysate). The degree of variance in the electrochemical sensor measurements was determined by comparing duplicate measurements for all experiments. The background signal level was determined by averaging the log10 results of the two negative control sensors and the log10 results of the four lowest species-specific probe pairs (from among the EC, PM, KE, PA, and EF sensors). A receiver operating characteristic (ROC) curve analysis (29, 52) was performed to determine the optimal threshold for a positive result to maximize the weighted accuracy, where weighted accuracy was defined as (5 x "sensitivity" + "specificity")/6 to account for the greater diagnostic importance of minimizing false-negative results than of minimizing false-positive results. Sensor results were determined in a three-step algorithm. First, the average of the log10 UNI results was compared with background to determine whether the specimen contained bacteria. Second, for specimens predicted to contain bacteria, the identity of the bacteria in the specimen was determined by comparing the average log10 result of the highest species-specific signal (from among the EC, PM, KE, PA, and EF sensors) with the background. Third, if no species-specific signal was positive, then the average log10 result of the EB probe pair was compared with the background to determine if the bacteria present in the specimen were members of the family Enterobacteriaceae.
|
View this table: [in a new window] |
TABLE 1. Sequences of capture and detector probe pairs used with electrochemical sensor arraya
|
|
View this table: [in a new window] |
TABLE 2. Species specificities of the uropathogen probe pairs used with the electrochemical sensor array
|
10,000 bacteria/ml and any species present at a concentration of
100,000 bacteria/ml were identified. Specimens with <10,000 bacteria/ml of 1 or 2 species or <50,000 bacteria/ml of >2 species were reported as "no significant growth." Specimens with <1,000 bacteria/ml were reported as "no growth." |
|
|---|
Development of probes for the "UTI chip." The electrochemical sensor was used to determine which probe pairs had the greatest sensitivity and specificity for binding to 16S rRNA in lysates of uropathogens. Capture and detector probes were designed to hybridize to species- and group-specific regions of the 16S rRNA molecule that are accessible to hybridization with oligonucleotide probes, as determined by prior flow cytometric analysis (14). Candidate probe pairs for E. coli, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus spp., Klebsiella spp., Enterobacter spp., and the Enterobacteriaceae group were tested for uropathogen detection sensitivity and specificity using the electrochemical sensor to arrive at the optimal probe set shown in Table 1.
Table 2 summarizes the observed specificities of the probe pairs using the electrochemical sensor array. Significant sequence similarities between Klebsiella and Enterobacter sp. 16S sequences precluded the design of species-specific probes for these organisms. The Enterococcus probe pair (EF) was specific for both Enterococcus faecalis and Enterococcus faecium. The universal probe pair (UNI) detects all of the uropathogens tested. Figure 2 shows detection by the EB probe pair of all members of the family Enterobacteriaceae tested, but not equal numbers of P. aeruginosa, Staphylococcus spp., or Enterococcus spp. As shown in Table 2 and Fig. 2, both the UNI and EB probes detect less common uropathogens, such as Citrobacter spp. and Morganella spp., for which species-specific probes are not yet available.
![]() View larger version (12K): [in a new window] |
FIG. 2. Specificities of Enterobacteriaceae-specific probe pairs. Positive signals were seen for all Enterobacteriaceae species tested but not for gram-positive uropathogens (Eo, Ef, Ss, and Sa) or P. aeruginosa (Pa). (See the footnote to Table 2 for bacterial species abbreviations.) Means and standard deviations of experiments performed in duplicate are shown. NC refers to the negative control experiments performed with capture and detector probes but without bacterial lysate.
|
![]() View larger version (24K): [in a new window] |
FIG. 3. Direct, species-specific detection of uropathogens in representative clinical urine specimens using the electrochemical sensor array. Current output for each of the probe pairs in the array are shown in nanoamperes. The mean current output of duplicate sensors is shown above each bar; the error bars represent the standard deviations. The probe pair designation is shown below each bar, and the species specificity is given in Table 2. The urinalysis and microbiological characteristics of each specimen are shown to the right of the bar graph. The background signal level was determined by averaging the log10 results of the NC sensors and the sensors with the four lowest species-specific probe pairs (from among EC, PM, KE, PA, and EF). As described in the text, significant signals were 0.30 log unit (5 standard deviations) above background. (A) E. coli in this clinical urine specimen produced significant signals in the UNI, EB, and EC sensors despite high numbers of white blood cells (WBC). RBC, red blood cells. (B) 16S rRNA from as few as 4 x 104 K. pneumoniae cells/ml in urine produced significant signal levels in the UNI, EB, and KE sensors.
|
|
View this table: [in a new window] |
TABLE 3. Urinalysis and microbiological characteristics of representative clinical urine specimens tested with the electrochemical sensor array containing seven probe pairs ("UTI chip")
|
The 16-sensor array allowed each of eight electrochemical sensor measurements (seven probe pairs plus one negative control) to be performed in duplicate. Sensor-to-sensor variance in the clinical study was determined by comparing the results from testing of all 78 samples, which yielded 1,248 (2 x 8 x 78) paired results. The duplicate residual errors were found to have a log normal distribution. The standard deviations of the duplicates were roughly constant at a value of 0.06 log units for all sensors in the UTI chip array. A receiver operating characteristic curve analysis found that the optimal UTI chip weighted accuracy was maximal at 91% for a mean log positive over mean log background threshold of 0.25 to 0.33 log units. A 0.30-log-unit threshold roughly equal to 5 standard deviations above background was applied for all sensor pairs in the array. As shown in Table 4, this approach yielded an overall sensitivity for detection of uropathogens in clinical urine specimens by the UNI probe pair of 54/58 (93%; standard error, ±3.3%). UNI probe specificity was estimated at 10/12 (83%; standard error, ±10.8%), although this number could not be determined with great accuracy because there were only 12 "no-growth" specimens in the sample. Because the signal interpretation algorithm was designed for specimens containing no more than one organism, it is difficult to make further estimates of specificity. However, we do note that there was only one incorrect species identification: one specimen containing S. marcescens was falsely positive by the PA probe pair.
|
View this table: [in a new window] |
TABLE 4. Results of a blinded study of clinical urine specimens showing a high level of sensitivity for detection of gram-negative bacteria by the "UTI Chip"a
|
![]() View larger version (41K): [in a new window] |
FIG. 4. "UTI Chip" signal interpretation algorithm. The three-step algorithm used to interpret the results of electrochemical-sensor experiments on 78 specimens that met inclusion criteria is shown. Positive signals were those with a mean log of greater than 0.30 log unit (5 standard deviations) over background. "UNI" and "EB" are eubacterial- and Enterobacteriaceae-specific probe signals, respectively. "Bkgnd" is the background signal, as defined in the text. "MaxSpSp" refers to the maximum species-specific signal. Clinical microbiology results are given in shaded boxes. Two-letter species abbreviations are given in the footnote of Table 2. NSG indicates "no significant growth." NG indicates "no growth." An asterisk indicates false-positive results, and false-negative results are underlined.
|
|
|
|---|
The sensor technique utilized here is an electrochemical sandwich assay in which target 16S rRNA is bound by both a capture and a detector probe (16). The capture probe anchors the target to the sensor, and the detector probe provides a means for recognizing target bound on the sensor surface. This sandwich strategy has been successfully employed in several types of electrochemical sensors (5, 7, 46, 50). In our system, as in most electrochemical sandwich assays, the detector probe is linked directly or indirectly to HRP for amperometric detection of redox current (5, 7, 50). An alternative electrochemical sandwich assay approach involving a ferrocene-modified detector probe has been described (46). When the detector probe is hybridized to the target on the sensor surface, the ferrocene moieties mediate electron transfer to the gold electrode via a phenylacetylene molecular wire embedded in the electrode's SAM. In any microfabricated electrochemical sensor, the SAM is essential for reducing background current by insulating the working electrode when a potential difference is applied between the working and reference electrodes (3). When our electrochemical sensor results are to be read, the sensor is placed in a potentiostat and a voltage of 200 mV is applied between the working and auxiliary electrodes, resulting in polarization of the working electrode with negative charges. HRP substrates, such as TMB, then serve to transfer electrons from the electrode surface to the HRP across the SAM (11, 16, 27).
Electrochemical sensors directly detect nucleic acid targets by hybridization, so that sensitivity and specificity problems associated with nucleic acid amplification in the presence of biological inhibitors are avoided. The accuracy of the "UTI chip" was demonstrated for samples with significant amounts of somatic cells and urinary protein and ranges of pH. In contrast, PCR detection assays for urine specimens are subject to false-negative results due to DNA polymerase inhibitors, which may not be removed even after a nucleic acid purification step (24, 25). Application of PCR assays to complex mixtures of nucleic acids can produce biased target amplification, resulting in problems with specificity (36, 44). We and others have encountered sensitivity and specificity problems related to sample contamination and/or urinary inhibitors in our attempts to use PCR for detection of uropathogens in clinical urine specimens (38, 45). Electrical and fluidics systems can be miniaturized, so electrochemical sensors are potentially less expensive and more portable than sophisticated optical detection systems currently being used in PCR detection assays. These intrinsic advantages may be critical when sensor technology is eventually applied in an automated point-of-care device.
We developed a library of species-specific probes that recognize over 90% of uropathogens submitted to the clinical microbiology laboratory. 16S rRNA was chosen as the sensor target because it exists in high copy numbers in bacterial cells and is an essential component of ribosomes. 16S rRNA gene sequences of the relevant species of bacteria are well characterized and contain regions of diversity and conservation that are useful for molecular diagnostic purposes (37). Similar to probes used for 16S rRNA-based fluorescence in situ hybridization assays, the oligonucleotide probes that were developed for use with the electrochemical sensor array hybridize with species-specific and surface-accessible regions of the 16S rRNA target molecule. The panel of probes described in the clinical-feasibility study was able to detect and identify a broad range of gram-negative uropathogens. The absence of a positive signal from the UNI probe effectively rules out a gram-negative bacterial UTI. Our detection system had reduced sensitivity for gram-positive uropathogens, such as Enterococcus species and S. saprophyticus. The most likely explanation for this problem is resistance of the gram-positive cell wall to the alkaline lysis method used in our study. Development of alternative lysis methods that would be applicable to all potential uropathogens is an area of active investigation in our laboratory.
A short time from specimen collection to readout is essential to an approach intended for a point-of-care application. Our current detection strategy requires approximately 45 min: bacterial lysis for 5 min, probe hybridization for 25 min, and enzyme amplification for 15 min. The amperometric reading is currently being measured at 60 s, by which point the current flow has reached steady state (Fig. 1D). The reaction kinetics in each step of the protocol is limited by passive diffusion (concentration of molecules versus time). We anticipate that the sample preparation time can be further reduced by optimization of bacterial-lysis efficiency and hybridization kinetics.
The optical-grade surface characteristics of the gold electrodes in our electrochemical sensor array allowed the formation of pinhole-free SAMs. Highly insulating SAMs improve sensitivity by reducing sensor background and increasing the signal-to-noise ratio. Sensitivity was also improved by integrating liquid phase detector probe-target hybridization for maximum signal detection efficiency and solid-phase probe-sensor immobilization for maximum target capture efficiency (16). The most commonly used microbiologic criterion for UTI is greater than 105 CFU/ml from a clean-catch voided urine sample (23, 51), although the actual concentrations of uropathogens in clinical urine specimens are frequently higher. A robust uropathogen diagnostic system should be able to detect and quantify bacteria over a wide spectrum of bacterial concentrations and urine parameters. The studies presented here indicate that the UTI chip is able to detect uropathogens over wide range of clinical urine characteristics (Table 3) and at bacterial concentrations as low as 4 x 104 CFU/ml (Fig. 3B). The results of the clinical-feasibility study proved this to be an appropriate level of sensitivity for detection of clinically relevant concentrations of bacteria in urine. Given that only 4 µl of the 60-µl lysate-probe mixture, or 1/15 of the total, is applied to the sensor surface, the ability to detect as few as 4.0 x 104 CFU/ml (Fig. 3B) translates to a total of 2,600 bacteria. E. coli contain between 5 x 103 and 2 x 104 copies of 16S rRNA per cell (31). Therefore, we estimate that the rRNA detection limit of the sensor is within the femtomolar (3 x 1016) range, which compares favorably with other electrochemical DNA sensors (8). This level of sensitivity is achieved using raw bacterial lysates from actual body fluids and represents an important advance compared to previous studies.
The studies presented here demonstrate the analytical and clinical validity of an electrochemical DNA sensor for quantitative, species-specific detection of uropathogens. The culture- and PCR-independent molecular identification was achieved in 45 min. The ability of the sensor to provide genotypic identification of uropathogens and to rapidly differentiate between bacterial pathogens is clearly superior to current clinical microbiology approaches, which are limited by the growth rates of bacteria and typically require at least 48 h from sample collection to reporting. The sensor array and the detection assay, in their present forms, are not yet ready for widespread application. Strategies for improving the sensitivity of the electrochemical assay for detection of uropathogens, particularly gram-positive bacteria, are being examined. Improvements in sensitivity should allow amperometric detection of clinically significant uropathogen concentrations below 10,000 CFU/ml, which would otherwise be considered "no significant growth" by current clinical microbiology standards. It is anticipated that detection of multiple uropathogens in a single clinical specimen will also be feasible. Eventually, testing of larger numbers of clinical specimens will be required to accurately determine the sensitivity and specificity of the electrochemical-sensor approach. The electrochemical sensor and the simplicity of its sample preparation requirements are compatible with eventual integration with an automated microfluidics-based sample preparation module. Concentration of bacteria in the urine sample, coupled with active mixing of reagents instead of passive diffusion, would significantly reduce overall sample preparation time and enhance sensitivity. Our studies lay the foundation for analyses of the clinical utility of our UTI chip. Rapid detection and identification of uropathogens at the point of care will have a profound impact on clinical decision making when managing a patient with suspected UTI.
This study was supported by Bioengineering Research Partnership grant EB00127 (to B.M.C.) from the National Institute of Biomedical Imaging and Bioengineering and in part by the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research. J.C.L. is the recipient of an American Foundation for Urologic Disease (AFUD) fellowship. We thank Frank W. Clark, Jr., for his early generous support.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»